FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

YOUNG JOHN D
2. Issuer Name and Ticker or Trading Symbol

PFIZER INC [ PFE ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Group President
(Last)          (First)          (Middle)

PFIZER INC.-CORP. SECRETARY, 235 EAST 42ND ST.
3. Date of Earliest Transaction (MM/DD/YYYY)

10/9/2019
(Street)

NEW YORK, NY 10017
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Phantom Stock Units SSP   (1) 10/9/2019    A     40.0000       (2)  (2) Common Stock  40.0000  $35.6900  43941.0000  D   

Explanation of Responses:
(1)  Each unit represents one phantom share of common stock.
(2)  These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
YOUNG JOHN D
PFIZER INC.-CORP. SECRETARY
235 EAST 42ND ST.
NEW YORK, NY 10017


Group President

Signatures
Susan E. Grant, by power of atty., for John D. Young 10/10/2019
**Signature of Reporting Person Date


Grafico Azioni Pfizer (NYSE:PFE)
Storico
Da Apr 2024 a Mag 2024 Clicca qui per i Grafici di Pfizer
Grafico Azioni Pfizer (NYSE:PFE)
Storico
Da Mag 2023 a Mag 2024 Clicca qui per i Grafici di Pfizer

Notizie Pfizer Inc - PFE

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Form S-8 - Securities to be offered to employees in employee benefit plans
Giovedì 9 Maggio 2024 (1 giorno fa) • Edgar (US Regulatory)
Bain Capital in Talks to Acquire PowerSchool; Blackstone Emerges Victorious in Hipgnosis Bidding War, and More News
Giovedì 9 Maggio 2024 (1 giorno fa) • IH Market News
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Mercoledì 8 Maggio 2024 (2 giorni fa) • Edgar (US Regulatory)
Pfizer Announces New Chief Strategy and Innovation Officer
Lunedì 6 Maggio 2024 (4 giorni fa) • Business Wire
CVS Health, Starbucks, Shares Weaker; Pinterest Soars
Mercoledì 1 Maggio 2024 (1 settimana fa) • IH Market News
Pfizer Reports First-Quarter 2024 Results
Mercoledì 1 Maggio 2024 (1 settimana fa) • Business Wire
FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer
Martedì 30 Aprile 2024 (2 settimane fa) • Business Wire
Pfizer Highlights Progress in Accelerating Breakthrough Cancer Medicines at ASCO 2024 Annual Meeting
Lunedì 29 Aprile 2024 (2 settimane fa) • Business Wire
Anglo American Rejects BHP Group’s Offer, Toyota Invests $1.4 Billion in Indiana, and More News
Venerdì 26 Aprile 2024 (2 settimane fa) • IH Market News
U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B
Venerdì 26 Aprile 2024 (2 settimane fa) • Business Wire
Pfizer Declares Second-Quarter 2024 Dividend
Mercoledì 24 Aprile 2024 (2 settimane fa) • Business Wire
Coca-Cola and Microsoft Sign Billion-Dollar Agreement, Apple Event Set for May 7, and More News
Mercoledì 24 Aprile 2024 (2 settimane fa) • IH Market News